Vnitr Lek 2016, 62(3):183-185

Clinical aspects of pharmacological treatment of diabetic neuropathy - cooperation with neurologists and diabetologists

Denisa Janíčková Žďárská, Milan Kvapil*
Interní klinika 2. LF UK a FN Motol, Praha

The development and progression of symptomatic diabetic neuropathy (SDN) is linked to hyperglycemia. The effort to improve compensation of diabetes mellitus during therapy is therefore very important. This is where the cooperation between the diabetologist and neurologist within therapy plays an important role. The pharmacological therapy of symptomatic sensitive peripheral diabetic neuropathy is difficult and with a less than satisfactory effect. A variety of active substances is used in symptomatic therapy, primarily designed for intervention in other pathological conditions. The recommended guidelines include antidepressants, anticonvulsants, opiates and their derivatives. However this therapy brings with it a relatively high incidence of adverse effects which detract from patients' adherence to treatment. Very good results are reached by the therapy with thioctacid.

Keywords: adverse side effects; diabetic neuropathy; therapy of diabetic neuropathy; thioctacid

Received: March 13, 2016; Accepted: March 18, 2016; Published: March 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Janíčková Žďárská D, Kvapil M. Clinical aspects of pharmacological treatment of diabetic neuropathy - cooperation with neurologists and diabetologists. Vnitr Lek. 2016;62(3):183-185.
Download citation

References

  1. Hughes RA. Peripheral neuropathy. BMJ 2002; 324(7335): 466-469. Go to original source... Go to PubMed...
  2. Tesfaye S, Boulton AJ, Dickenson AH. Mechanisms and management of diabetic painful distal symmetrical polyneuropathy. Diabetes Care 2013; 36(9): 2456-2465. Go to original source... Go to PubMed...
  3. Doporučené postupy pro diagnostiku a léčbu diabetické retinopatie - aktualizace 2011. Dostupné z WWW: <http://www.diab.cz/standardy>.
  4. Ziegler D, Hanefeld M, Ruhnau KJ et al. Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant alpha-lipoic acid. A 3-week multicentre randomized controlled trial (ALADIN Study). Diabetologia 1995; 38(12): 1425-1433. Go to original source... Go to PubMed...
  5. Ziegler D, Nowak H, Kempler P et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a meta-analysis. Diabet Med 2004; 21(2): 114-121. Go to original source... Go to PubMed...
  6. Kvapil M. Postavení fixní kombinace antidiabetik v terapii. Remedia 2013; 23(4): 266-269.
  7. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care 1997; 20(10): 1512-1517. Go to original source... Go to PubMed...
  8. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with Type 2 diabetes: a retrospective cohort study. Diabet Med 2002; 19(4): 279-284. Go to original source... Go to PubMed...
  9. Deli G, Bosnyak E, Pusch G et al. Diabetic neuropathies: diagnosis and management. Neuroendocrinology 2013; 98(4): 267-280. Go to original source... Go to PubMed...
  10. Ziegler D, Low PA, Litchy WJ et al. Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial. Diabetes Care 2011; 34(9): 2054-2060. Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.